Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03077633
Other study ID # OBX0038
Secondary ID
Status Withdrawn
Phase Phase 2/Phase 3
First received March 3, 2017
Last updated March 20, 2018
Start date October 1, 2017
Est. completion date January 17, 2018

Study information

Verified date March 2018
Source Mednax Center for Research, Education, Quality and Safety
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective randomized control trial that will compare cervical cerclage plus vaginal progesterone to vaginal progesterone along in twin pregnancies complicate by a short cervix (</= 15.0mm) between 16w0d to 25w6d.


Description:

A prospective Randomized Trial that will test whether treatment with cervical cerclage plus vaginal progesterone improves pregnancy outcomes among women with twin pregnancy at 16 0/7 to 25 6/7 weeks of gestation who have a cervical length (CL) of 0.1 to 15.0 mm on transvaginal ultrasound exam, the rate of preterm birth at less than 32 weeks of gestation (PTB<32 wks.) and the rate of adverse perinatal outcome will be lower in those treated with cervical cerclage plus vaginal progesterone than in those treated with vaginal progesterone alone.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 17, 2018
Est. primary completion date January 17, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Twin pregnancy (see Exclusion Criterion (a) below re: monochorionic twins)

- Gestational age 16 0/7 to 25 6/7 weeks at time of enrollment by best-estimated age.

- Cervical length 0.1 to 15.0 mm on transvaginal ultrasound examination. (Cervical length is taken to mean the length of the closed portion of the cervical canal.

Exclusion Criteria:

- Maternal age less than 18 years

- Monochorionic twins (such as monochorionic-diamniotic, monochorionic-monoamniotic, or conjoined twins)

- Rupture of membranes, either twin

- One or both twins has no cardiac activity

- One or both twins has known or suspected major malformation, aneuploidy, or polyhydramnios

- Maternal congenital uterine anomaly (such as bicornuate uterus, unicornuate uterus)

- Pregnancy started as triplets or higher-order multifetal gestation and then reduced to twins, either spontaneously or via procedure

- Symptomatic uterine contractions, 6 or more per hour

- Ongoing bleeding from uterus

- Patient declines to consider cerclage

- Patient declines treatment with vaginal progesterone

- Allergy to progesterone or peanuts (because the vaginal progesterone formulation used will be a capsule of micronized progesterone in peanut oil.)

- Cerclage is already in place

- Cerclage placement is judged to be technically impossible

- Patient has a history of poor follow-up or poor adherence to physician recommendations

- Patient is planning to relocate outside the local area before the end of pregnancy such that delivery records will be unavailable

- Patient does not give consent to participate in this trial.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Cervical Cerclage placement
Cervical Cerclage placement
Drug:
Vaginal Progesterone
200mg tab of vaginal progesterone administered daily from time of randomization until delivery.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Mednax Center for Research, Education, Quality and Safety

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of very preterm birth (PTB) Rate of very PTB (PTB less than 32 weeks) Time frame measured on the date the infant is born. We anticipate this time frame to be approximately 16 weeks.
Primary Rate of adverse perinatal outcome The rate of adverse perinatal outcome defined as any one or more of the following: Miscarriage, stillbirth, neonatal death, respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage (grade III or IV), necrotizing enterocolitis, culture proven sepsis. Time frame measured 28 days after the infant is born. We anticipate this time frame to be approximately 28 weeks.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Completed NCT05502510 - Assessing the Effectiveness and Efficacy of the MyHealthyPregnancy Application
Not yet recruiting NCT03418311 - Cervical Pessary Treatment for Prevention of s PTB in Twin Pregnancies on Children`s Long-Term Outcome N/A
Not yet recruiting NCT03418012 - Prevention of sPTB With Early Cervical Pessary Treatment in Women at High Risk for PTB N/A
Completed NCT02993744 - Maternal Inflammatory Parameters Within Routine Treatment With Betamethasone N/A
Active, not recruiting NCT02673216 - Infection and Adverse Pregnancy Outcome
Completed NCT01683565 - Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood Phase 4
Completed NCT01460576 - Improving Prematurity-Related Respiratory Outcomes at Vanderbilt N/A
Completed NCT01412931 - Protein and Ultrasound Indicators of Preterm Birth N/A
Completed NCT02606058 - The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures? N/A
Terminated NCT03715530 - Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women N/A
Completed NCT00422526 - Progesterone for Prevention of Preterm Birth in Women With Short Cervix: Randomized Controlled Trial Phase 3
Enrolling by invitation NCT04251260 - Effectiveness of Positioning in Preterm Neonates N/A
Completed NCT03668860 - India Dexamethasone and Betamethasone Phase 1
Recruiting NCT03638037 - Correlation Between Maternal Vitamin D Level And Preterm Birth
Completed NCT02225353 - Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery Phase 2
Recruiting NCT03992534 - The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth Phase 1
Completed NCT03144141 - Association Between EHG and Risk of Preterm Delivery in Women Hospitalized for Threatened Premature Delivery N/A
Completed NCT05210985 - Examination of the Relationship Between Home Affordances With Development
Completed NCT04021654 - What is the Future of Vulnerable New-borns